Related Experiment Videos
A structured approach to the management of purpura fulminans
Insights
Fresh frozen plasma (FFP) effectively manages acute purpura fulminans (PF) and disseminated intravascular coagulation. This approach allows safe sequential trials of antithrombotic, antiplatelet, antifibrinolytic, and antiproteolytic agents for tailored PF treatment.
Area of Science:
- Hematology
- Pediatric Medicine
- Critical Care
Background:
- Purpura fulminans (PF) is a rare, life-threatening condition characterized by purpura and coagulopathy.
- Disseminated intravascular coagulation (DIC) is a common complication of PF, necessitating prompt management.
- Previous treatment strategies for PF have varied, with limited consensus on optimal protocols.
Observation:
- A 5-year-old boy with acute PF and DIC was successfully treated using a protocol initiated with fresh frozen plasma (FFP).
- FFP administration controlled acute DIC, enabling the safe evaluation of subsequent therapeutic agents.
- Two PF cases, one acute and one chronic, responded to FFP, with the acute case showing heparin responsiveness and the chronic case showing coumarin responsiveness.
Findings:
- Initial FFP administration is recommended over heparin to mitigate hemorrhage risk while ensuring a rapid response in PF.
- A sequential therapeutic approach, starting with FFP, allows for systematic investigation of venous antithrombotics, antiplatelets, antifibrinolytics, and antiproteolytics.
- The study highlights differential responses to anticoagulants (heparin vs. coumarin) in PF, suggesting distinct underlying mechanisms.
Implications:
- This protocol provides a structured framework for managing PF and its associated DIC, prioritizing patient safety and therapeutic efficacy.
- The findings suggest that FFP can serve as a crucial initial step, paving the way for targeted therapies based on individual PF case characteristics.
- This approach facilitates a deeper understanding of PF pathogenesis by using therapeutic agents as investigative tools.
Abstract:
A 5-year-old boy with purpura fulminans (PF) was successfully managed with a protocol in which fresh frozen plasma (FFP) was administered, followed by a trial of certain therapeutic agents. This approach was based upon combined experience both with the reference patient and with a subject with a chronic form of PF. FFP controlled the acute disseminated intravascular coagulation in both instances and permitted venous antithrombotic drugs to be evaluated in safety. The PF syndrome in the index case was found to be heparin responsive, while the atypical case was coumarin responsive (heparin resistant). Initial administration of FFP was recommended rather than heparin in order to minimize the risk of hemorrhage while maintaining the likelihood of a swift response. When FFP is effective, a sequential trial should be undertaken with agents from the following categories: (1) venous antithrombotic, (2) antiplatelet, (3) antifibrinolytic, and (4) antiproteolytic. This process permits therapies to be thoroughly tested and used as investigative probes into the mechanisms of a particular case of PF. Should FFP prove ineffective, the list can serve as a guide for the investigation of various fastacting agents in the acute phases of disseminated intravascular coagulation. PF treatments are ranked in accordance with the number of positive outcomes in the literature.